---
title: "Moderna | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 1.016 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264643547.md"
datetime: "2025-11-06T12:08:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264643547.md)
  - [en](https://longbridge.com/en/news/264643547.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264643547.md)
generator: "portal-rs"
---

# Moderna | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 1.016 B

Revenue: As of FY2025 Q3, the actual value is USD 1.016 B, beating the estimate of USD 869.89 M.

EPS: As of FY2025 Q3, the actual value is USD -0.51, beating the estimate of USD -2.1792.

EBIT: As of FY2025 Q3, the actual value is USD -333 M.

### Segment Revenue

-   **Total Revenue**: $1.0 billion for Q3 2025, a 45% decrease from $1.9 billion in Q3 2024, primarily due to a 47% decrease in net product sales, mainly from lower COVID vaccine sales.
-   **COVID Vaccine Sales**: $971 million in Q3 2025, with $781 million from U.S. sales and $190 million from international sales.
-   **RSV Vaccine Sales**: $2 million in Q3 2025.

### Operational Metrics

-   **Net Loss**: - $200 million for Q3 2025, compared to net income of $13 million in Q3 2024.
-   **Cost of Sales**: $207 million for Q3 2025, a 60% decrease from Q3 2024, reflecting lower inventory write-downs and reduced unutilized manufacturing capacity.
-   **Research and Development Expenses**: $801 million for Q3 2025, a 30% decrease from Q3 2024, due to investment prioritization and efficiency gains.
-   **Selling, General and Administrative Expenses**: $268 million for Q3 2025, a 5% decrease from Q3 2024.

### Cash Flow

-   **Cash Position**: $6.6 billion as of September 30, 2025, down from $7.5 billion as of June 30, 2025, primarily due to seasonal impacts on working capital.

### Unique Metrics

-   **Operating Expenses**: Expected to improve by $0.7 billion to a range of $5.2 - $5.4 billion for 2025.

### Outlook / Guidance

-   **Revenue Guidance**: Narrowed 2025 projected revenue range to $1.6 - $2.0 billion.
-   **Year-End Cash Balance**: Expected to increase by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion.
-   **Cost of Sales for 2025**: Expected to be approximately $0.8 to $0.9 billion, lowered from $1.2 billion.

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Sandhar Technologies Limited Beat Revenue Forecasts By 11%: Here's What Analysts Are Forecasting Next](https://longbridge.com/en/news/304746660.md)
- [US military says it disabled cargo vessel in Gulf of Oman](https://longbridge.com/en/news/304743184.md)
- [Li Auto (LI) Launches The Li i6 As Fair Value Stays In Focus](https://longbridge.com/en/news/304741271.md)
- [VSBLTY Partners With QuadGen to License AI Platform for India’s Smart Cities](https://longbridge.com/en/news/304742065.md)
- [Kinetiq: Oku pledges 40% of net trading fees to KNTQ buybacks and burns - 07 Nov 2026](https://longbridge.com/en/news/304740703.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**